This article examines valuation methodologies for two ASX-listed entities—ResMed (RMD) and QBE Insurance—positioning them as potential investment candidates for 2026. The piece adopts a neutral, educational posture by presenting frameworks for equity analysis rather than making directional calls, which limits immediate market-moving impact.
ResMed operates in cloud-connected medical devices and software, serving respiratory and sleep apnea markets. The company's growth profile depends on recurring SaaS revenue and aging demographics. Valuation multiples in this space typically compress during rising-rate environments, suggesting sensitivity to macro conditions rather than company-specific catalysts in this article.
The dual-ticker format (RMD and QBE) indicates a comparative value exercise with minimal sector coherence—health care versus insurance have distinct yield curves and risk profiles. This mixed approach dilutes conviction signals and suggests promotional rather than analytical depth.
Sector implication: Health Care defensive characteristics (aging population tailwinds) remain stable, but valuations remain vulnerable to cost-of-capital shifts. Insurance sector exposure adds cyclical exposure, creating divergent tailwinds. No earnings surprises, regulatory shifts, or M&A signals are evident; this is primarily a valuation tutorial with low institutional relevance.